Selva therapeutics inc
WebJun 9, 2024 · Selva Therapeutics, Inc. (“Selva”) announced that its antiviral drug candidate SLV213 has been shown to be effective against three prominent variants of SARS-CoV-2 in a preclinical study. Previously reported preclinical studies in cell systems showed potent antiviral effect against the Washington isolate (the original strain) of SARS-CoV-2. ... WebSelva Therapeutics Announces First Dosing in Phase 1 Clinical Study of SLV213, a Potential Oral Treatment for COVID-19 (Businesswire) - "Selva Therapeutics, Inc. announced today that the company has received U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for SLV213 for the treatment of COVID-19 and …
Selva therapeutics inc
Did you know?
WebFeb 3, 2024 · Selva Therapeutics has reported that the Phase I clinical study of a potential oral Covid-19 treatment, SLV213, met its primary objective of demonstrating safety and tolerability. A small molecule drug candidate, … WebFor the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing …
WebFeb 2, 2024 · Selva Therapeutics is a privately held biotechnology company dedicated to the development of therapeutics for infectious diseases. By rapidly developing SLV213 for … WebJul 21, 2024 · Selva Therapeutics is a privately held biotechnology company dedicated to the development of therapeutics for infectious diseases.
WebNov 12, 2024 · Selva Therapeutics is a privately held biotechnology company dedicated to the development of therapeutics for infectious diseases. By rapidly developing SLV213 for COVID-19, Selva Therapeutics intends to bring a valuable treatment to the market that has the potential to fight multiple life-threatening infectious diseases.
WebNov 12, 2024 · About Selva Therapeutics. Selva Therapeutics is a privately held biotechnology company dedicated to the development of therapeutics for infectious …
WebApr 20, 2024 · SAN DIEGO, April 20, 2024 -- ( BUSINESS WIRE )-- Selva Therapeutics, Inc. ("Selva") today announced new preclinical data demonstrating dosing of SLV213 at picomolar concentrations delivered... saint mary\u0027s university gaelsWebSelva Therapeutics is a privately held biotechnology company dedicated to the development of therapeutics for infectious diseases. By rapidly developing SLV213 for COVID-19, Selva … thimble tiny homesWebJul 21, 2024 · Selva Therapeutics, Inc., a San Diego, CA-based biotechnology company, raised $3m in Series A financing. The company intends to use the funds to advance SLV213 into clinical trials as an oral drug ... saint mary\u0027s university facultyWebSan Diego, CA 153 followers Selva is developing therapeutic drugs for coronaviruses (SARS-CoV-2), filoviruses (Ebola) and Chagas Disease. Follow See all 4 employees About us … saint mary\u0027s university gymWebFeb 2, 2024 · Selva Therapeutics is a privately held biotechnology company dedicated to the development of therapeutics for infectious diseases. By rapidly developing SLV213 for … thimble trail anza borregoWebFeb 2, 2024 · Preclinical studies in nonhuman primates suggest SLV213 has the potential to be effective for therapeutic and prophylactic use. SAN DIEGO--(BUSINESS WIRE)--#COVID19--Selva Therapeutics, Inc. today announced that the Phase 1 clinical study met its primary objective of demonstrating safety and tolerability of SLV213, a potential oral treatment for … saint mary\u0027s university halifax addressWebSelva Therapeutics is a biotechnology company dedicated to the development of therapeutics for infectious diseases. Headquarters Location San Diego, California, United States Suggest an edit Missing: Selva Therapeutics 's Product Demo & Case Studies Promote your product offering to tech buyers. thimble thumb